Idorsia

Idorsia

Verified
The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.

Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$1.2b (Public information from Jul 2024)
Company register number CH-280.3.020.963-7
Allschwil Canton of Basel-Landschaft (HQ)
Deals in current and previous year:

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
CHF2019202020212022202320242025
Revenues0000000000000000000000000000
% growth-201 %(51 %)175 %30 %79 %15 %
EBITDA0000000000000000000000000000
% EBITDA margin(1943 %)(586 %)(1666 %)(806 %)(347 %)(117 %)(96 %)
Profit0000000000000000000000000000
% profit margin(2072 %)(620 %)(1795 %)(853 %)(323 %)(184 %)(133 %)
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000
R&D % of revenue1841 %531 %1172 %395 %---

Source: Dealroom estimates

  • Edit
Get premium to view all results
DateInvestorsAmountRound
investor

$0.0

round
N/A

$0.0

round
investor

$0.0

round
N/A

$0.0

round
N/A

$0.0

round
*
N/A

CHF75.0m

Post IPO Debt
Total Funding000k

Recent News about Idorsia

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by Idorsia

Edit
Vaxxilon
ACQUISITION by Idorsia Jul 2020